Skip to content
Disclosery

Krensavage Asset Management, LLC

Follow

13F filer, CIK 1609251, NEW YORK, NY

Krensavage Asset Management, LLC reported $169,025,000 across 12 holdings for the quarter ended 2024-12-31, in a 13F-HR/A filed 2025-02-18. Its ten largest share positions make up 98.79% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0001609251-25-000002

Period
2024-12-31
Reported value
$169M
Holdings
12
Top 10 weight
98.79%
New
0
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ENTAadded+619,316$3.56M
INDIVIOR PLCadded+233,807$2.91M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
EXELreduced-315,746-$10.5M
UTHRreduced-8,275-$2.92M
BIIBreduced-4,579-$700K
BNTXreduced-4,920-$561K
JAZZreduced-4,454-$549K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR/A 0001609251-25-000002, largest first. % of portfolio is the value over $169,025,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 100,332 shares; 2024Q4: 92,057 shares 92,057$32.5M19.22%-8,275Timeline
EXELEXELIXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,281,612 shares; 2024Q4: 965,866 shares 965,866$32.2M19.03%-315,746Timeline
CAHCARDINAL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 210,263 shares; 2024Q4: 208,845 shares 208,845$24.7M14.61%-1,418Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 113,502 shares; 2024Q4: 108,923 shares 108,923$16.7M9.85%-4,579Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 110,257 shares; 2024Q4: 105,803 shares 105,803$13M7.71%-4,454Timeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,498,074 shares; 2024Q4: 2,117,390 shares 2,117,390$12.2M7.2%+619,316Timeline
INDIVIOR PLCINDIVIOR PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 701,873 shares; 2024Q4: 935,680 shares 935,680$11.6M6.88%+233,807
BNTXBIONTECH SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 93,583 shares; 2024Q4: 88,663 shares 88,663$10.1M5.98%-4,920Timeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 150,205 shares; 2024Q4: 149,196 shares 149,196$7.2M4.26%-1,009Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 251,495 shares; 2024Q4: 238,136 shares 238,136$6.85M4.05%-13,359Timeline
VNDAVANDA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 414,684 shares; 2024Q4: 378,762 shares 378,762$1.81M1.07%-35,922Timeline
MURAL ONCOLOGY PUB LTD COMURAL ONCOLOGY PUB LTD COQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 75,868 shares; 2024Q4: 70,163 shares 70,163$226K0.13%-5,705

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REGNREGENERON PHARMACEUTICALS353$371Kshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001609251-25-000001 superseded2025-02-18acceptance time not in the bulk data set
13F-HR/A 0001609251-25-000002 baserestatement2025-02-18acceptance time not in the bulk data set